| Name | Title | Contact Details |
|---|
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Havas Health houses Havas Life (formerly known as Euro RSCG Life), Health4brands (H4B), and Havas Lynx, three wholly-owned Health and Communications Networks, and defines policies and processes for the entire group. Its customer-centric approach has the talent, tenacity and technology that companies, brands and people need to thrive in today`s world.
Comprehensive NeuroScience, Inc. is a Hollywood, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Austin-based Superior HealthPlan (Superior) is a managed care company that employs more than 3,400 people across nine Texas offices. Superior is a wholly-owned subsidiary of Centene Corporation, a diversified, multi-national healthcare enterprise. Superior is licensed by the Texas Department of Insurance and is a Qualified Health Plan issuer in the Texas Health Insurance Marketplace.
Los Ninos Services is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.